posted stronger-than-expected third quarter earnings Tuesday, while boosting its full-year profit forecast, thanks in part to solid gains for its new cancer treatments.
Pharmaceuticals sales were up 5.1% to $13.9 billion while Medtech sales jumped 10% to $7.46 billion. Consumer health sales were spun-off to Kenvue, the group's stand-alone entity, earlier this year.
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오:
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
Johnson & Johnson Reports Earnings Tuesday. What to ExpectAn update in August after the split leaves investors with fewer questions for Tuesday's results.
출처: MarketWatch - 🏆 3. / 97 더 많은 것을 읽으십시오 »
Johnson & Johnson earnings: What to expectJohnson & Johnson is not expected to produce big surprises in its earnings release due Tuesday
출처: MarketWatch - 🏆 3. / 97 더 많은 것을 읽으십시오 »
Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surgeIt marks J&J’s first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.
출처: NBCLA - 🏆 319. / 59 더 많은 것을 읽으십시오 »
Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surgeIt marks J&J’s first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.
출처: NBCNewYork - 🏆 270. / 63 더 많은 것을 읽으십시오 »
Johnson & Johnson's stock climbs after company beats earnings estimates and raises profit guidanceJohnson & Johnson raised its full year EPS guidance and lifted the midpoint of its sales range
출처: MarketWatch - 🏆 3. / 97 더 많은 것을 읽으십시오 »